ValiGen Signs 5-Year Subscription Deal with Celera | GenomeWeb

NEW YORK, Sept 28 - ValiGen has signed a five-year deal to subscribe to all of Celera Genomic’s (NYSE: CRA) database products, the companies said Thursday.

Valigen, of Newton, PA, said it would access the databases through Celera’s web-based Discovery System.

Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.